BMS Adds To String Of Pearls: $470 Mil. Deal With French Biotech Brings Innate Immunity Approach Into Its R&D Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
BMS deal with Innate Pharma strengthens the U.S. company's focus on cancer immunotherapy, and adds fillip to biotech companies in France.